Can the peptide receptor radionuclide therapy [ 177 Lu]Lu-DOTA-TATE provide a net benefit for NET patients?

Authors :: Caplin ME
Source :: EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.] [EJC Suppl] 2021 Nov 09; Vol. 16, pp. 1-4. Date of Electronic Publication: 2021 Nov 09 (Print Publication: 2021).
Publication Year :: 2021
Abstract: Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Professor Martyn Caplin has received speaker and research honoraria from Advanced Accelerator Applications International, Ipsen, Novartis and Pfizer.

Language :: English
ISSN :: 1359-6349
Volume :: 16
Database :: MEDLINE
Journal :: EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.]
Publication Type :: Editorial & Opinion
Accession number :: 34912477
Full Text :: https://doi.org/10.1016/j.ejcsup.2021.06.001

Full Text Access

Tools